IPOs

  • Lufax launches roadshow for $2.36bn US IPO

    Lufax launches roadshow for $2.36bn US IPO

    Lufax Holdings, a personal finance services platform, has opened books for its offering of American depositary shares (ADS). It is aiming to raise up to $2.36bn.

  • Soltec Power rides ESG momentum with €150m IPO

    Soltec Power rides ESG momentum with €150m IPO

    Soltec Power Holding, the Spanish maker of solar trackers for renewable energy generation, has narrowed the price range for its IPO on the Spanish Stock Exchange, after the deal was covered shortly after the launch of bookbuilding earlier this week.

  • Canal+ Polska launches Warsaw IPO

    Canal+ Polska launches Warsaw IPO

    Emerging market IPOs have been one of the hottest themes in EMEA equity capital markets this year and issuance is set to continue as Canal+ Polska, the Polish television network owned by French TV service Canal+, launched its IPO on Thursday.

  • Ant comes closer to jumbo listing as investors vie for $35bn deal

    Ant comes closer to jumbo listing as investors vie for $35bn deal

    China’s Ant Group kicked off marketing for its Hong Kong and Shanghai dual listing on Thursday, the last stage before launching a possible $35bn IPO, set to be the world’s largest to date. The combined offering is already more than a third covered by onshore investors, with global buyers lining up for the rest. Addison Gong and Jonathan Breen report.

  • Link Mobility trades up after $650m flotation

    Link Mobility trades up after $650m flotation

    Link Mobility, the Norwegian provider of business to consumer messaging and mobile services, has begun trading on the Oslo Børs following the completion of its Nkr6bn ($650m) IPO.

  • GDS Holdings covers HK secondary offering

    GDS Holdings covers HK secondary offering

    Chinese data centre operator GDS Holdings has covered the books for its Hong Kong secondary offering, just hours after launching a deal that could be worth about $1.6bn.

  • Simcere Pharma nets $461m from top-end pricing

    Simcere Pharma nets $461m from top-end pricing

    Simcere Pharmaceutical Group has bagged HK$3.57bn ($460.6m) from its IPO, after sealing the offer at the top end of the price guidance, according to a source familiar with the deal.

IPO Archive